Evaluate for Private Equity
Build the commercial case behind pharma and biotech investments
Evaluate helps private equity teams screen pharma and biotech targets, assess market potential, pressure-test valuation assumptions and monitor the clinical, regulatory and commercial signals that could affect company performance.
Why private equity teams use Evaluate
In pharma and biotech private equity, the investment case depends on more than finding an attractive asset or company.
PE teams need to understand market size, revenue durability, competitive pressure, pipeline risk, regulatory milestones, pricing dynamics and the levers that could create value during ownership.
Evaluate brings together company, asset, forecast, pipeline, deal and catalyst intelligence so teams can screen targets, validate assumptions, monitor portfolio risks and support value creation with greater confidence.
drugs across marketed and pipeline assets
biopharma companies across private and listed markets
event types covering clinical, regulatory, legal and commercial catalysts
Used by 98% of the top 50 pharma companies
Trusted intelligence across the pharma and biotech ecosystem
Built for investment teams, trusted across pharma and biotech.
- Forecasts to 2032 for forward-looking market sizing and investment evaluation
- Historic sales data back to 1996 for long-term performance context
- Coverage across private and listed biopharma companies, marketed products and pipeline assets
Built for key private equity workflows
Get in touch
Whether you are building a target list, running commercial due diligence, preparing an investment committee memo, supporting a portfolio company or planning for exit, Evaluate helps you build a clearer view of the opportunity, risks and path to value.
Target screening and market mapping
Identify pharma and biotech companies, assets and market segments that could represent attractive investment opportunities.
Use Evaluate to screen companies, review portfolios, assess market exposure, compare peer groups and identify where commercial performance, pipeline strength and market growth align.
Useful when you need to:
- Build target lists around therapy areas, geographies or market segments
- Identify companies with marketed products or clinical-stage pipelines
- Compare companies by portfolio, forecast potential or market exposure
Commercial due diligence
Test whether the commercial opportunity supports the investment case.
Use Evaluate to assess current and forecast product sales, indication strategy, competitive intensity, pipeline strength, regulatory milestones, pricing dynamics and market risks before moving forward with a transaction.
Useful when you need to:
- Validate market size and growth assumptions
- Review current and forecast product sales
- Assess competitive threats, pipeline risk and commercial durability
Investment committee support
Build stronger investment recommendations with clearer evidence.
Use Evaluate to support IC discussions with data on market opportunity, revenue outlook, competitive dynamics, forecast potential, clinical and regulatory milestones, peer companies and comparable assets.
Useful when you need to:
- Strengthen investment memos
- Pressure-test valuation and growth assumptions
- Benchmark companies against relevant peers
Portfolio value creation
Support portfolio companies throughout the holding period with stronger market and competitive intelligence.
Use Evaluate to monitor product performance, track competitors, review market dynamics and identify strategic options across business development, licensing, market expansion and product strategy.
Useful when you need to:
- Support portfolio strategy and growth planning
- Identify market expansion or BD opportunities
- Monitor competitive threats that could affect performance
Competitive threat and catalyst monitoring
Track the events that could affect a target company, portfolio asset or investment thesis.
Use Evaluate Biomedtracker to monitor competing products, pipeline entrants, trial readouts, regulatory decisions, product launches, patent events, litigation, pricing shifts and M&A activity across relevant therapy areas and companies.
Useful when you need to:
- Monitor portfolio risk
- Track competitor activity and market disruption
- Prepare for valuation-impacting events
Exit and deal benchmarking
Assess the potential path to exit by understanding comparable companies, deal activity, IPOs, licensing agreements and M&A trends.
Use Evaluate to benchmark opportunities against relevant market activity and understand how similar companies or assets have been valued, partnered, financed or acquired.
Useful when you need to:
- Support IPO or sale preparation
- Identify potential acquirers or strategic partners
- Build a clearer exit narrative
Valuation and scenario planning
Assess how different commercial, competitive and regulatory assumptions could affect asset or company value.
Use Evaluate’s NPV tools and forecast data to model future sales, competitive launches, biosimilar risk, pricing, costs, tax changes and other variables that may influence valuation.
Useful when you need to:
- Pressure-test valuation assumptions
- Build or validate investment models
- Compare upside and downside cases
The data and tools behind the workflows
Evaluate gives private equity teams a connected view of the companies, assets, forecasts, pipelines, events, deals and market commentary behind pharma and biotech investment decisions.
Consensus forecasts and sales data
Size markets, assess historic and future sales potential, and benchmark assets across therapy areas, indications and companies.
Company and asset coverage
Track private and listed biopharma companies, marketed products, pipeline assets and company portfolios.
Pipeline intelligence
Review development stage, indication focus, clinical progress and competitor activity to understand future growth potential and risk.
NPV Analyzer
Model asset value using adjustable assumptions across future sales, pricing, competitive threats, risk and development scenarios.
Calendar of Events
Monitor clinical, regulatory, legal and commercial catalysts that could affect market perception, company value or portfolio strategy.
Peer Group Analyzer
Compare companies against relevant peers to support target screening, market mapping, benchmarking and IC discussions.
Report Builder
Create focused views of companies, drugs, therapy areas or development stages to support target list creation and diligence workflows.
M&A, licensing and deal intelligence
Assess acquisitions, licensing deals, IPOs, exits and comparable company activity to benchmark opportunities, validate valuations and support investment and exit planning.
News & Insights
Keep up to date with the market signals shaping pharma and biotech investment decisions through expert analysis, exclusive interviews and market commentary from Scrip, In Vivo, Pink Sheet and Medtech Insight, covering key deals, strategy shifts, leadership changes, regulatory developments and wider biopharma market trends.
Build stronger pharma and biotech investment strategies with Evaluate
See how Evaluate helps private equity teams screen targets, assess market potential, pressure-test valuations, monitor portfolio risks and support value creation with trusted biopharma intelligence.
Frequently Asked Questions
How can Evaluate support private equity target screening?
Evaluate helps PE teams identify and assess pharma and biotech companies by market exposure, product portfolio, pipeline strength, forecast potential, therapy area focus and competitive position.
This supports target list creation, market mapping and early prioritization before deeper diligence.
How does Evaluate support commercial due diligence?
Evaluate provides intelligence on current and forecast sales, market size, pipeline activity, competitive threats, regulatory milestones, pricing dynamics and relevant catalysts.
This helps teams test whether the commercial opportunity supports the investment case and identify risks that could affect future performance.
Can Evaluate help with valuation and scenario planning?
Yes. Evaluate’s forecast data and NPV tools help teams model asset value and test assumptions around future sales, pricing, development timelines, competitive launches, biosimilar risk and other commercial variables.
This can support investment modelling, IC preparation and upside/downside case development.
Can Evaluate support portfolio value creation?
Yes. PE teams can use Evaluate to monitor portfolio company performance, track competitors, assess market expansion opportunities and identify business development, licensing or partnership options.
This helps teams stay close to the market during the holding period and support strategic planning.
How can Evaluate help with exit planning?
Evaluate helps teams benchmark comparable companies, assess relevant deal activity, identify potential acquirers or partners, and understand the market dynamics that could shape the exit narrative.
This can support IPO preparation, sale planning, strategic positioning and investor materials.
